Amobarbital Production Cost Reports

The report provides detailed analysis essential for establishing an amobarbital production plant. It encompasses all critical aspects necessary for amobarbital production, including the cost of amobarbital production, amobarbital plant cost, amobarbital production costs, and the overall amobarbital production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an amobarbital production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Amobarbital Market Analysis: Demand and Supply Analysis, and Sourcing

Amobarbital is a barbiturate sedative and hypnotic used in a small set of clinical roles. Chemically it is a barbituric acid with an ethyl and an isopentyl group at the 5 position. It works by enhancing the action of GABA in the brain, which slows the central nervous system. The drug once treated insomnia and anxiety widely, but safer medicines have replaced it in most settings. Listed as a controlled substance, it carries tight licensing and a narrow, declining demand. First made in the 1920s, it is an old molecule now used mainly in niche and legacy roles. Today the drug is scheduled, closely tracked, and made in small volumes.

Buyers are a small group of licensed pharmaceutical makers and controlled-substance distributors. Demand runs through legacy sedative products, some injectable use, and specialist neurology applications. Supply is concentrated in a handful of licensed plants across the US, Europe, and a few regulated Asian countries. An amobarbital demand and supply analysis has to weigh malonate and urea cost, controlled-substance quotas, licensing burden, and a shrinking end market. On receipt, buyers check assay by HPLC, related barbiturates, residual solvents, heavy metals, and water content.

Summary of the Product, Grades, and Uses

Amobarbital carries the molecular formula C11H18N2O3 and a molar mass of 226.27 g/mol under CAS 57-43-2. It is a white crystalline powder that is almost insoluble in water and dissolves in alcohol and dilute base. The melting point runs around 156 to 158 °C, and it is odorless with a slightly bitter taste. Being a weak acid, it forms a soluble sodium salt, amobarbital sodium, used in injectable products. It is hygroscopic, so it is kept dry and sealed through handling and storage. In storage, it holds up well when kept cool, dry, sealed, and away from moisture.

Amobarbital reaches the market in a few grades. Pharmaceutical grade meets USP, European Pharmacopoeia, and BP monographs for human medicine. The sodium salt is supplied for injectable and rapid-onset products under the same tight limits. Physically it ships as a fine crystalline powder to suit tableting, capsule, and injection blending. Buyers check assay by HPLC, related barbiturates, residual solvents, heavy metals, and microbial limits against the specification.

Across the label, the roles span sedation, sleep, seizure control, and specialist neurology. In legacy medicine, it was used for insomnia, preoperative sedation, and anxiety before safer agents took over. In current practice, it appears in some injectable sedation, seizure control, and a diagnostic brain test called the Wada procedure. The rapid, deep sedation and the injectable salt keep it useful in a few settings. Across these uses, the value comes from strong sedation, a rapid injectable form, and a long clinical record. Demand is niche and slowly shrinking. Safer drugs keep displacing it. Reference and research use is small, mostly analytical and pharmacology work in labs.

Main End-Uses of Amobarbital

The main use of amobarbital is as a sedative and hypnotic barbiturate, and this covers most of the small demand. In practice, it goes into tablets, capsules, and injectable products based on the sodium salt. Buyers are licensed pharmaceutical formulators who run controlled-substance lines. Used as a bulk active, one batch serves a limited number of finished doses. On the buyer side, checks cover assay, related barbiturates, residual solvents, and dissolution. For a controlled barbiturate API, the sensitive attributes are related barbiturates, assay, residual solvents, and color.

Legacy sedative and hypnotic use is the largest remaining setting. Older products used it for insomnia, anxiety, and preoperative calm, though most of these have moved to safer medicines. Some markets still keep it for specific sedation and seizure roles under specialist control. On this narrow demand, buyers weigh licensing, purity, related barbiturates, and reliable supply. Here the value comes from deep, reliable sedation, the injectable salt, and a long history. Barbiturates are an old class. Safety limits their use. Formulators value a clean impurity profile here, since the product goes into people.

Specialist and diagnostic use is the second setting. In neurology, the injectable form supports the Wada test, which maps language and memory before brain surgery. Some emergency and anesthesia settings keep it for deep sedation and seizure control. On the specification side, the key attributes are related barbiturates, assay, residual solvents, and heavy metals. Reference and comparator use accounts for the small remainder of demand, covering analytical standards, method development, and pharmacology work in labs.

Amobarbital Market Risks

Amobarbital sits in the controlled-substance market, so its main risks are regulation and shrinking demand rather than price competition. Demand is narrow and slowly falling, since safer sedatives and anticonvulsants have replaced it in most care. Controlled-substance status brings quotas, licensing, and heavy oversight that limit who can make and trade it. Supply leans on a few licensed plants, so any closure or license change moves the whole small market. Diversion and misuse risk keep the drug under strict security and tracking. On balance, the main pressures are declining demand, controlled-substance rules, supply concentration, and security burden. The market is small. Compliance is heavy. Most risk sits on regulation and volume.

Amobarbital manufacturing carries its own risks because the malonate chemistry and controlled-substance handling both demand tight control. The dialkylation of the malonate has to place both groups cleanly, or related barbiturates and side products build up. The condensation with urea has to run to a clean, on-assay barbiturate. Related barbiturates and unreacted intermediates are specified impurities that have to be kept low for a pharmaceutical grade. Every gram is tracked under controlled-substance rules, so losses and reconciliation are watched closely. Most rejected batches trace back to related barbiturates, assay, and residual-solvent failures.

Amobarbital Production Process and Main Cost Drivers

The amobarbital production process runs the full value chain, from diethyl malonate and urea receipt through dialkylation, condensation, acidification, purification, crystallization, and drying.

1. By Dialkylation of Diethyl Malonate and Condensation with Urea: The main inputs are diethyl malonate, ethyl bromide, isoamyl bromide, sodium ethoxide, urea, acid, organic solvents & purified water.

Amobarbital production opens with receipt and QC of diethyl malonate, the alkyl halides, and urea. Diethyl malonate is deprotonated with sodium ethoxide and alkylated first with an ethyl group and then with an isoamyl group. Built in this step is diethyl ethyl-isopentylmalonate, the disubstituted malonate ester. Checked before the next step, this intermediate has to be clean, since a poor dialkylation carries impurities, side esters, and color forward.

Next, the disubstituted malonate is condensed with urea in the presence of sodium ethoxide, which closes the six-membered barbiturate ring. The reaction mixture is then acidified to free amobarbital from its sodium salt and precipitate the crude product. The crude is treated with carbon, then crystallized, filtered, dried & milled to specification. Across the process, the critical controls are dialkylation selectivity, ring-closure completeness, related barbiturates, and color. Moisture is kept low, since the product is hygroscopic. Reconciliation runs throughout under controlled-substance rules. QC covers assay, related barbiturates, residual solvents & water content. The main levers on cost are alkylation selectivity, ring-closure yield, purification recovery & compliance overhead.

Main Factors Affecting Amobarbital Production Cost

Amobarbital production cost is shaped mainly by yield across the alkylation and condensation and by the heavy compliance overhead. The raw materials, diethyl malonate, the alkyl halides & urea, are cheap commodity chemicals, so feedstock is not the main driver. Because the route runs several chemical steps, yield losses compound and shape the cost per kilogram. Sodium ethoxide, acid & solvents are steady process costs. Energy for the reactions, purification & drying is a real utility item. On the testing side, HPLC for related barbiturates, residual-solvent & water tests make up part of the QC spend. On the running side, the biggest cost lines are labor, compliance, energy, and low-volume overhead. Compliance is a major driver. Yield losses come next.

Unit cost also moves with batch size and controlled-substance overhead. A small, licensed plant spreads security, licensing & reconciliation costs over few kilograms, which lifts the unit cost. Because every gram is tracked, documentation and reconciliation add labor that a normal API does not carry. Controlled-substance security, vaulting & audit are ongoing fixed costs. GMP documentation, pharmacopoeia compliance & regulatory upkeep are carried as fixed overhead. The synthesis train, purification & controlled-substance infrastructure all carry heavy fixed overhead, so a plant running at low volume spreads that overhead over fewer kilograms and lands at a higher unit cost.

Raw Materials for Amobarbital Production Plant and its Procurement

Raw material sourcing for amobarbital centers on cheap, widely available commodity chemicals. Diethyl malonate is the primary building block, made at large fine-chemical plants from chloroacetic acid or similar feedstocks. It ships from many suppliers, since malonate esters are common industrial chemicals. Ethyl bromide, isoamyl bromide, sodium ethoxide, urea, acid, solvents & purified water complete the input streams.

The cheapest malonate is not always the cheapest route to finished amobarbital. A feed with related esters or impurities carries side products through the alkylation. Feedstock quality also shapes the related-barbiturate profile, which is critical for a pharmaceutical grade. Taken together, malonate purity, alkylation selectivity, ring-closure yield, solvent recovery & purification recovery drive most of the variable cost per kilogram.

These sensitivities shape how an amobarbital plant buys and qualifies its inputs. Contracts specify malonate and alkyl-halide purity, related impurities, color & moisture, and every incoming lot is quarantined until QC release. Vendor qualification runs through supplier audits, review of the supply chain & lot-to-lot monitoring. On the incoming side, checks cover assay, related impurities, color, and moisture. Long-term agreements with two malonate suppliers help steady both cost and timing. Because the product is controlled, the plant itself carries the heaviest qualification burden, since licensing and security shape the whole operation.

Sustainability and Regulatory Requirements

Amobarbital manufacture raises environmental concerns that center on solvent use, alkyl-halide handling & salt effluent. Standard controls rely on solvent recovery, scrubbing of alkyl-halide vapors, salt and chemical effluent treatment & safe destruction of off-spec controlled material. Alkyl halides are the sharpest handling concern, since they are volatile and hazardous, so containment and scrubbing matter. Solvent recovery and energy integration cut both cost and footprint. On the sustainability side, the themes are solvent recovery, halide containment, effluent treatment, and safe destruction. Destruction of controlled waste is witnessed and documented, since every gram is tracked. Controlled destruction is the sharpest issue. Full documentation is expected.

Regulatory obligations for amobarbital follow from its status as a controlled barbiturate. In the US, the API sits under FDA cGMP per 21 CFR 210/211, the USP monograph, and DEA controlled-substance rules as a scheduled drug. In Europe, an EU GMP site and national controlled-substance licenses are needed for regulated supply. ICH Q7 for active ingredients applies, along with BP, EP & USP limits including related barbiturates. International trade runs under import and export permits and INCB oversight. On the compliance side, the duties span cGMP, the compendial monograph, controlled-substance licensing, and secure handling. Sites carry vaulting, reconciliation & audit systems, and batch release rests on assay, related barbiturates, residual solvents & microbial limits.

CAPEX and OPEX for an Amobarbital Production Plant

An amobarbital plant is a small, secure synthesis and purification facility built for controlled-substance work. Plant investment starts with malonate and alkyl-halide storage, an alkylation reactor, and a condensation reactor with solvent handling. From there come an acidification and work-up section, a purification and carbon-treatment step, and a crystallization, drying & milling suite. Utilities cover chilled brine, steam, purified water, solvent recovery, vapor scrubbing & an effluent treatment plant. On the QC side, a laboratory block houses HPLC, related-barbiturate testing, residual-solvent & water analysis. Civil works provide contained reactor bays, a solvent store, a secure vault for controlled material & a controlled-access warehouse. On the capital side, the big blocks are the synthesis reactors, the purification train, the security and vaulting systems, and the drying suite. Controlled-substance security runs through the whole site, since every gram is tracked.

Amobarbital operating cost comes from the same inputs and control points that shape the process. The variable side is led by malonate, the alkyl halides, urea, reagents & solvents, alongside energy, labor, testing, effluent treatment, packaging & freight. Cost per kilogram then comes down to alkylation selectivity, ring-closure yield & compliance overhead. The amobarbital plant setup cost depends on capacity, synthesis and purification scale, security scope & grade range. Taken together, yield, labor, energy, security & compliance determine the running cost.

Plant Location and Investment Factors

A workable amobarbital site sits in a jurisdiction that grants controlled-substance licenses and offers secure infrastructure. Access to trained synthesis, QC, and compliance staff is essential. The US and Europe host most licensed barbiturate capacity, backed by strong regulatory and security systems. A few regulated Asian countries add licensed capacity for export under permits. These regions offer the licensing framework, secure supply chains & regulatory credibility that a controlled substance needs. The site also needs vaulting, reconciliation systems & a full effluent treatment plant for chemical waste.

For an amobarbital plant, the main investment decision is whether the small, declining market justifies a dedicated controlled-substance facility at all. Building a licensed plant is costly, and the narrow demand limits the volume to spread that cost over. Sharing a multi-barbiturate or multi-controlled-substance site helps carry the security and compliance overhead across more products. Whether to serve regulated human markets or niche specialist demand is the other decision, since both need tight quality and licensing. Plant scale has to match a small, shrinking market, so the project rests on compliance strength and niche positioning. For a maker in this space, licensing, security & compendial quality matter most. The market is small. Compliance defines it.

Major Amobarbital Producing Regions

The US, Europe, and a few regulated Asian countries are the core production regions for amobarbital today. The US and Europe host most licensed barbiturate capacity, backed by strong controlled-substance systems and specialty API makers. Regional strength rests on licensing, security, quality, and regulatory credibility rather than low cost. A few regulated Asian countries add licensed capacity that exports under import and export permits. Because the market is small and controlled, only seven to nine facilities worldwide are thought to supply the API. Across the map, the value chain spans commodity malonate, alkyl halides, controlled synthesis, and secure finishing. A new plant would most likely sit within an existing licensed controlled-substance site rather than stand alone.

Key Amobarbital Producers

Siegfried Holding

• Ranks among the leading Western makers of controlled-substance and barbiturate APIs.
• Runs licensed, FDA-inspected sites in Europe and the US for scheduled drugs.
• Competes on regulated-market quality, controlled-substance handling & multi-site reliability.
• Regulatory record covers US FDA, EU GMP & full ICH Q7 compliance.

Delphis Pharma

• Operates as a barbiturate API maker and contract manufacturer serving domestic and export markets.
• Produces amobarbital and related barbiturates under controlled-substance licensing.
• Competes on barbiturate focus, contract capacity & a competitive cost base.
• Regulatory work covers national registration and export documentation.

Hosbon Pharmaceutical

• Supplies amobarbital and other controlled APIs under licensed, permit-based trade.
• Runs synthesis and export supply from a regulated Asian base.
• Competes on controlled-substance capability, capacity & a competitive cost base.
• Regulatory work covers national registration and export permits.

Alcaliber

• Specializes in controlled-substance and narcotic APIs from its European base.
• Produces barbiturates and related scheduled drugs under strict licensing.
• Competes on controlled-substance expertise, security & regulated-market quality.
• Regulatory record covers EU GMP and controlled-substance compliance.

Cambrex

• Manufactures a broad API range, including controlled substances, from its US and European sites.
• Runs licensed synthesis and secure handling for scheduled and specialty drugs.
• Competes on regulated-market quality, capacity & controlled-substance systems.
• Regulatory record covers US FDA, EU GMP & multi-country approvals.

Macfarlan Smith

• Ranks among the established makers of controlled-substance APIs from its UK base.
• Runs licensed synthesis and secure handling for scheduled drugs.
• Competes on controlled-substance heritage, security & regulated-market quality.
• Regulatory record covers UK and EU GMP with controlled-substance compliance.